{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:31:32Z","timestamp":1786123892812,"version":"build-2736575974"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors enhance immune recognition of tumors by interfering with the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed death 1 (PD1) pathways. In the past decade, these agents brought significant improvements to the prognostic outlook of patients with metastatic cancers. Recent data from retrospective analyses and a few prospective studies suggest that checkpoint inhibitors have activity against brain metastases from melanoma and nonsmall cell lung cancer, as single agents or in combination with radiotherapy. Some studies reported intracranial response rates that were comparable with systemic ones. In this review, we provide a comprehensive summary of clinical data supporting the use of anti-CTLA4 and anti-PD1 agents in brain metastases. We also touch upon specific considerations on the assessment of intracranial responses in patients and immunotherapy-specific toxicities. We conclude that a subset of patients with brain metastases benefit from the addition of checkpoint inhibitors to standard of care therapeutic modalities, including radiotherapy and surgery.<\/jats:p>","DOI":"10.1093\/neuros\/nyaa095","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T15:21:26Z","timestamp":1583508086000},"page":"E281-E288","source":"Crossref","is-referenced-by-count":30,"title":["Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons"],"prefix":"10.1227","volume":"87","author":[{"given":"Elisa","family":"Aquilanti","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Neuro-Oncology, Department of Neurology, Stephen E. Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"},{"name":"Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Cancer Program, Broad Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Neuro-Oncology, Department of Neurology, Stephen E. Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Cancer Program, Broad Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9]]},"reference":[{"issue":"1","key":"bib1-20231011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/now127","article-title":"Updates in the management of brain metastases","volume":"18","author":"Arvold","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"5256","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"8","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"issue":"5","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"22","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"bib10-20231011","first-page":"867","article-title":"The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells","volume":"60","author":"Moran","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ygyno.2015.06.033","article-title":"Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma","volume":"138","author":"Stringer-Reasor","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"505","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10105","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet North Am Ed"},{"issue":"4","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"21","key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet North Am Ed"},{"issue":"11","key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"10066","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet North Am Ed"},{"issue":"2","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1200\/JCO.2016.34.15_suppl.9038","article-title":"Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets)","volume":"34","author":"Jonathan Wade Goldman","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/1759-7714.12963","article-title":"Pembrolizumab for non-small cell lung cancer with central nervous system metastases: a two-case report","volume":"10","author":"Di","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13256-017-1334-z","article-title":"Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report","volume":"11","author":"Pluchart","year":"2017","journal-title":"J Med Case Rep"},{"issue":"15_suppl","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1200\/JCO.2018.36.15_suppl.2009","article-title":"Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab","volume":"36","author":"Goldberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"bib35-20231011","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12885-018-4371-0","article-title":"Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer","volume":"18","author":"Jin","year":"2018","journal-title":"BMC Cancer"},{"issue":"15_suppl):","key":"bib36-20231011","doi-asserted-by":"crossref","first-page":"e16103","DOI":"10.1200\/JCO.2016.34.15_suppl.e16103","article-title":"Incidence of brain metastases in metastatic renal cell carcinoma in the era of targeted therapies","volume":"34","author":"Bowman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"bib37-20231011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"7_suppl.):","key":"bib40-20231011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.2019.37.7_suppl.546","article-title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): results from KEYNOTE-427 cohort B","volume":"37","author":"McDermott","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10189","key":"bib41-20231011","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"bib42-20231011","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.19.00639","article-title":"Brain metastases in renal cell carcinoma: immunotherapy responsiveness is multifactorial and heterogeneous","volume":"37(23)","author":"Reed","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"bib43-20231011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"issue":"2","key":"bib44-20231011","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-018-2880-y","article-title":"Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity","volume":"139","author":"Diao","year":"2018","journal-title":"J Neurooncol"},{"issue":"5","key":"bib45-20231011","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"bib46-20231011","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1016\/j.ijrobp.2016.06.922","article-title":"Initial report on safety and lesion response of melanoma brain metastases after stereotactic radiosurgery or hypofractionated radiation therapy in patients receiving concurrent pembrolizumab","volume":"96","author":"Anderson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"bib47-20231011","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/neuros\/nyy203","article-title":"BRAF V600 mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases: a multicenter retrospective study","volume":"84","author":"Mastorakos","year":"2019","journal-title":"Neurosurgery"},{"issue":"2","key":"bib48-20231011","first-page":"333","article-title":"Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases","volume":"132","author":"Singh","year":"2019","journal-title":"J Neurosurg"},{"issue":"8","key":"bib49-20231011","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol"},{"issue":"3","key":"bib50-20231011","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent pd-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"bib51-20231011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"issue":"3","key":"bib52-20231011","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2014.12.FOCUS14698","article-title":"Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series","volume":"38","author":"Jones","year":"2015","journal-title":"Neurosurg Focus"},{"issue":"5","key":"bib53-20231011","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"bib54-20231011","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"bib55-20231011","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"issue":"16","key":"bib56-20231011","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"bib57-20231011","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"bib58-20231011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J Neurosurg"},{"issue":"2","key":"bib59-20231011","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"bib60-20231011","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ijrobp.2012.07.208","article-title":"Risk factors for radiation necrosis after radiosurgery for brain metastases","volume":"84","author":"Sneed","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"bib61-20231011","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"bib62-20231011","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the response assessment in neuro-oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol"},{"issue":"3","key":"bib63-20231011","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"bib64-20231011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/2326-6066.CIR-15-0160","article-title":"Melanoma brain metastasis pseudoprogression after pembrolizumab treatment","volume":"4","author":"Cohen","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"bib65-20231011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11912-018-0722-x","article-title":"Pseudoprogression of melanoma brain metastases","volume":"20","author":"Simard","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"15","key":"bib66-20231011","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"bib67-20231011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"bib68-20231011","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neurosurgery\/article-pdf\/87\/3\/E281\/33643897\/nyaa095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyaa095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:42:08Z","timestamp":1786120928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyaa095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyaa095","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]}}}